Brian M Thomas, MD
Fax: (724) 260-7222
Business hours
| Monday | 9:00am to 4:00pm |
| Tuesday | 9:00am to 4:00pm |
| Wednesday | 9:00am to 4:00pm |
| Thursday | 9:00am to 4:00pm |
| Friday | 9:00am to 4:00pm |
| Saturday | - |
| Sunday | - |
About us
Brian M Thomas, MD, is a medical oncologist and hematologist passionate about medical oncology, hematology, healthcare delivery, public policy, and government. He has led healthcare network initiatives focused on physician productivity, the implementation of quality metrics in cancer care, and other projects within AHNCI, including Moonshot enrollment. Dr. Thomas completed his fellowship in medical oncology and hematology at The University of Texas MD Anderson Cancer Center in Houston, Texas, and his residency in internal medicine through the Osler Medical Housestaff Training Program at The Johns Hopkins Hospital in Baltimore, Maryland. During his oncology fellowship, he worked to increase cancer screening rates at Houston's largest Federally Qualified Health Center, participated in leadership roles within MD Anderson's Comprehensive Cancer Control Program, and served on the Texas Medical Association's Committee on Cancer. During his residency, he served as President of The Maryland State Medical Society Resident and Fellow Section, spearheading initiatives to improve health literacy and preventative health in Baltimore. Dr. Thomas was elected Chair of the Minnesota Medical Association Medical Student Section and received the University of Minnesota President's Service and Leadership Award. During his training, he chaired several American Medical Association committees and served on the MEDPAC Board of Directors and the Maryland State Medical Society.
| Languages | English |
| Services | liver cancer, fibrolamellar carcinoma, personal history of cancer, secondary cancer screening, long term side effects of cancer treatment, personal history of radiation therapy, personal history of chemotherapy, blood cancer chemotherapy, autoimmune neutropenia (ain), evans syndrome, hemophilia inhibitors, factor thirteen deficiency, factor seven deficiency, hereditary elliptocytosis (he), prostate cancer chemotherapy, bladder cancer chemotherapy, testicular cancer chemotherapy, relapsed acute myelogenous leukemia (aml), relapsed non hodgkin lymphoma, relapsed hodgkin lymphoma, relapsed acute lymphoblastic leukemia (all), neutrophil disorders, blastic plasmacytoid dendritic cell neoplasm, disseminated intravascular coagulation, carcinoma of unknown primary, lymphomatoid granulomatosis, intrathecal chemotherapy, maintenance chemotherapy, consolidation chemotherapy, induction chemotherapy, pituitary cancer, chronic myelomonocytic leukemia, malignant adnexal tumor, peripheral t cell lymphoma, intraarterial chemotherapy of tumors, brain metastases, coagulation disorders, bone marrow failure syndromes, waldenstrom macroglobulinemia, liver metastases, adrenal nodules, hodgkin lymphoma, cancer genetics, hemoglobinopathies, thrombocytosis, acute blood loss anemia, blood disorders, lymphopenia, prostate cancer, early detection of cancer, von willebrand disease, adenocarcinoma of lung, acute myelogenous leukemia (aml), acute lymphoblastic leukemia (all), abdominal chemotherapy, multiple endocrine neoplasia type 2b, multiple endocrine neoplasia type 2a, multiple endocrine neoplasia type 2, multiple endocrine neoplasia type 1, papillary cancer of thyroid, medullary cancer of thyroid, follicular cancer of thyroid, poems syndrome, squamous cancer of the lung, esophageal cancer, kasabach merritt phenomenon (kmp), anemia of chronic disease, familial aplastic anemia, cooley anemia, pernicious anemia, hemolytic anemia, retroperitoneal mass, acute promyelocytic leukemia, prolymphocytic leukemia, primary myelofibrosis, oral complications of cancer, non hodgkin lymphoma, myeloproliferative diseases, lymphoid leukemia, lymphedema therapy, large granular lymphocytic leukemia, hematologic malignancies, head and neck cancer, cancer related fatigue, hereditary cancer risk, bone marrow disorders, blood cancer, adverse effects to anticoagulants, adult t cell leukemia, head and neck tumors, reduced intensity conditioning regimens, lymphoblastic lymphoma, germinoma, fanconi anemia, epithelioid hemangioendothelioma, diamond blackfan anemia, bladder cancer, cancer screening, thyroid cancer |
| Video | https://www.youtube.com/watch?v=i6upAHwiKqM |